9 patents
Utility
Anti-CD73 antibodies and uses thereof
28 Mar 23
Provided are anti-CD73 antibodies or fragments thereof.
Zhengyi Wang, Lei Fang, Bingshi Guo, Jingwu Zang
Filed: 10 Feb 20
Utility
Anti-PD-L1 antibodies and uses thereof
11 Jan 22
Provided are anti-PD-L1 antibodies or fragments thereof.
Lei Fang, Yongqiang Wang, Zhengyi Wang, Bingshi Guo, Jingwu Zang
Filed: 29 Mar 19
Utility
Fusion Proteins Containing CD47 Antibodies and Cytokines
1 Apr 21
The present invention provides fusion proteins containing cytokines and novel CD47 antibodies or immunologically active fragments thereof, as well as pharmaceutical compositions containing such fusion proteins that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation.
Zhengyi Wang, Wei Cao, Lei Fang, Bingshi Guo
Filed: 12 Nov 18
Utility
Anti-PD-L1 antibodies and uses thereof
27 Jul 20
Provided are anti-PD-L1 antibodies or fragments thereof.
Lei Fang, Zhengyi Wang, Bingshi Guo, Jingwu Zang
Filed: 8 Aug 18
Utility
Novel CD47 Monoclonal Antibodies and Uses Thereof
6 May 20
The present invention provides novel CD47 antibodies or immunologically active fragments thereof that have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination, as well as pharmaceutical compositions containing such antibodies that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation.
Zhengyi Wang, Lei Fang, Bingshi Guo, Jingwu Zang
Filed: 19 Oct 17
Utility
Anti-CD73 antibodies and uses thereof
9 Mar 20
Provided are anti-CD73 antibodies or fragments thereof.
Zhengyi Wang, Lei Fang, Bingshi Guo, Jingwu Zang
Filed: 22 Jan 18
Utility
Anti-LAG-3 antibodies and uses thereof
2 Mar 20
The present disclosure provides antibodies that bind Lymphocyte Activation Gene-3 (LAG-3).
Lei Fang, Zhengyi Wang, Bingshi Guo, Jingwu Zang, Wenqing Jiang, Yongqiang Wang
Filed: 21 Feb 18
Utility
Modified CK and CH1 Domains
25 Dec 19
Provided are antibody and antigen-binding fragment with modified Cκ and CH1 domains that still enable pairing of the Cκ and CH1 domains but have reduced pairing compared to wild type CH1 and Cκ domains without the modification.
Yongqiang Wang, Lei Fang, Zhengyi Wang, Bingshi Guo, Jingwu Zang
Filed: 14 Jan 19
Utility
ANTI-PD-L1 Antibody and IL-7 Fusions
20 Nov 19
Provided are fusion molecule having a PD-L1 inhibitor fused to a human IL-7 protein or fragment thereof through a peptide linker.
Lei Fang, Feifei Cui, Haijuan Gu, Zhengyi Wang, Bingshi Guo
Filed: 24 Jan 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first